No KYC. 100x Leverage. $100 Welcome Bonus. Crypto Futures Trading Made Easy on BexBack.

SINGAPORE, Oct. 24, 2025 (GLOBE NEWSWIRE) — With Bitcoin's price fluctuating below $110,000, many analysts predict a prolonged period of high volatility in the crypto market. Holding spot positions may struggle to generate short-term profits in such conditions. As a result, 100x leverage futures trading has become the preferred tool for seasoned investors looking to […]

Merus’ Interim Data on Petosemtamab in Metastatic Colorectal Cancer Demonstrates Monotherapy Activity and Robust Response Rate in Combination with FOLFOX/FOLFIRI with Well Tolerated Safety

(NasdaqGM:MRUS), – 100% response rate in 1L left-sided mCRC (n=8, confirmed and unconfirmed) – 62% response rate in 2L left- and right-sided mCRC (n=13, confirmed and unconfirmed) UTRECHT, The Netherlands and CAMBRIDGE, Mass., Oct. 24, 2025 (GLOBE NEWSWIRE) — Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), an oncology company developing innovative, full-length

Remix Therapeutics Announces Positive Preliminary Data from Phase 1 Study of REM-422 in Patients with Adenoid Cystic Carcinoma at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Preliminary Results Yield 43% Overall Response Rates (via RECIST) in the Efficacy Population Data Demonstrate REM-422, the First-in-Class Small Molecule MYB mRNA Degrader, Reduces Expression of the MYB Oncogene WATERTOWN, Mass., Oct. 24, 2025 (GLOBE NEWSWIRE) — Remix Therapeutics (Remix), a clinical-stage biotechnology company developing small molecule therapies to modulate RNA processing and address the

Halda Therapeutics Announces First-in-Human Results for HLD-0915, an Oral RIPTAC(TM) Therapeutic Demonstrating Encouraging Safety and Anti-Tumor Activity in Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Anti-tumor activity was observed in heavily pretreated mCRPC patients across all dose cohorts; in 22 patients who completed at least 2 cycles of therapy, 59% achieved PSA50 response and 32% achieved PSA90 response All 5 patients (5/5) with measurable disease according to RECIST criteria achieved a partial response (PR), all by the first response assessment

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arcturus Therapeutics Holdings Inc. – ARCT

(NasdaqGM:ARCT), NEW YORK, Oct. 24, 2025 (GLOBE NEWSWIRE) — Pomerantz LLP is investigating claims on behalf of investors of Arcturus Therapeutics Holdings Inc. (“Arcturus” or the “Company”) (NASDAQ: ARCT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Arcturus and certain of its officers and/or directors

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mr. Cooper Group Inc. – COOP

(NASDAQ:COOP), NEW YORK, Oct. 24, 2025 (GLOBE NEWSWIRE) — Pomerantz LLP is investigating claims on behalf of investors of Mr. Cooper Group Inc. (“Mr. Cooper” or the “Company”) (NASDAQ: COOP). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Mr. Cooper and certain of its officers

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Molina Healthcare, Inc. of Class Action Lawsuit and Upcoming Deadlines – MOH

(NYSE:MOH), NEW YORK, Oct. 24, 2025 (GLOBE NEWSWIRE) — Pomerantz LLP announces that a class action lawsuit has been filed against Molina Healthcare, Inc. (“Molina” or the “Company”) (NYSE: MOH).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in WPP Plc of Class Action Lawsuit and Upcoming Deadlines – WPP

(NYSE:WPP), NEW YORK, Oct. 24, 2025 (GLOBE NEWSWIRE) — Pomerantz LLP announces that a class action lawsuit has been filed against WPP Plc (“WPP” or the “Company”) (NYSE: WPP). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in RCI Hospitality Holdings, Inc. of Class Action Lawsuit and Upcoming Deadlines – RICK

(NasdaqGM:RICK), NEW YORK, Oct. 24, 2025 (GLOBE NEWSWIRE) — Pomerantz LLP announces that a class action lawsuit has been filed against RCI Hospitality Holdings, Inc. (“RCI” or the “Company”) (NASDAQ: RICK). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in KBR, Inc. of Class Action Lawsuit and Upcoming Deadlines – KBR

(NYSE:KBR), NEW YORK, Oct. 24, 2025 (GLOBE NEWSWIRE) — Pomerantz LLP announces that a class action lawsuit has been filed against KBR, Inc. (“KBR” or the “Company”) (NYSE: KBR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include

Scroll to Top